Ensysce Biosciences (ENSC) Change in Accured Expenses (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Change in Accured Expenses of -$342521.0 for Q3 2025, down 113.08% year-over-year from $2.6 million in Q3 2024, and down 825.51% quarter-over-quarter from -$37009.0 in Q2 2025.
Ensysce Biosciences (ENSC) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Change in Accured Expenses for 8 consecutive years, with -$342521.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Accured Expenses fell 113.08% year-over-year to -$342521.0; the TTM figure through Sep 2025 stood at $184830.0 (down 80.61% YoY), while the FY2024 annual figure was $43927.0, up 135.56% from the prior year.
- Change in Accured Expenses declined to -$342521.0 in Q3 2025 per ENSC's latest filing, from -$37009.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.2 million in Q3 2021 and bottomed at -$987997.0 in Q2 2023.
- Historically, Change in Accured Expenses has averaged $172161.2 across 5 years, with a median of $86450.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 2063.57% — and 2024, when it plunged 533.61%.
- Ensysce Biosciences' Change in Accured Expenses stood at -$323228.0 in 2021, then surged by 115.51% to $50134.0 in 2022, then surged by 2063.57% to $1.1 million in 2023, then tumbled by 83.81% to $175562.0 in 2024, then tumbled by 295.1% to -$342521.0 in 2025.
- Business Quant data shows ENSC's Change in Accured Expenses at -$342521.0 in Q3 2025, -$37009.0 in Q2 2025, and $388798.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -342,521.00 |
| Sep 30, 2025 | -342,521.00 |
| Jun 30, 2025 | -37,009.00 |
| Jun 30, 2025 | -37,009.00 |
| Mar 31, 2025 | 388,798.00 |
| Mar 31, 2025 | 388,798.00 |
| Dec 31, 2024 | 175,562.00 |
| Dec 31, 2024 | 175,562.00 |
| Sep 30, 2024 | -160,748.00 |
| Sep 30, 2024 | -160,748.00 |
| Jun 30, 2024 | 162,938.00 |
| Jun 30, 2024 | 162,938.00 |
| Mar 31, 2024 | -133,825.00 |
| Mar 31, 2024 | -133,825.00 |
| Dec 31, 2023 | 1.08 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | -25,370.00 |
| Sep 30, 2023 | -25,370.00 |
| Jun 30, 2023 | -987,997.00 |
| Jun 30, 2023 | -987,997.00 |